The National Comprehensive Cancer Network® and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research for the optimal management of hematologic toxicities of PARP inhibitors (PARPi). Pfizer (hereafter, “Grantor”) is providing $1 Million in funding to support research studies to advance the understanding of mechanisms and formulating the optimal management of hematologic toxicity of PARPi in the treatment of patients with prostate cancer. The Grantor will serve as the funding organization. Grants are available only to investigators from NCCN Member Institutions.
A multi-disciplinary approach is encouraged. Members may include, but are not limited to: Urologists, Medical Oncologists, Hematologists, Basic Scientists, Radiation Oncologists) and other allied prostate cancer healthcare providers.
Proposal submission deadline: Sep. 18, 2024 (was July 23)
• NCCN Member Institutions only. • Collaboration between NCCN Member Institutions is strongly encouraged in order to foster the interactive sharing of knowledge and expertise, and to utilize the combined clinical strengths of members, particularly in the case of uncommon tumors. Although the submitting investigator must be from an NCCN Member Institution, participating co-investigators do not need to be at an NCCN Member Institution. This can also include crossinstitutional collaboration. • Proposal submissions from Junior Faculty are encouraged. • Trainees may participate as a sub-investigator under the appropriate mentorship from a PI from a NCCN Member Institution
• A total of $1 Million is available to fund all projects. • The intent is to fund 2-5 studies. All budgets must include line-item information and a robust justification. • Clinical trials will be capped at a maximum of $500,000.00 (Including direct and indirect costs) • Quality and Pre-clinical will be capped at a maximum of $250,000.00 (Including direct and indirect costs)